September Milestones

Sept 25: Final Adaptations to ICER’s Value Assessment Framework Learn more

Every few years, we revisit ICER’s Value Assessment Framework, which is the backbone of ICER’s rigorous, transparent evidence reports that, as a basis for broader stakeholder and public engagement, will help the United States evolve toward a health care system that provides sustainable access to high-value care for all patients. Read the 2023 Value Assessment Framework. 

Register here for the Sept 28th webinar explaining all of the changes. 

Sept 28: Value Assessment Framework Webinar Learn more

In an upcoming webinar, President Steven Pearson, MD, MSc, and President-Elect Sarah Emond, MPP, will summarize the philosophy behind ICER’s approach to value assessment, as well as several key updates that will be implemented in the near term.

Register here for the Sept 28th webinar explaining all of the changes. 

Sept 29: Metachromatic Leukodystrophy — Virtual Public Meeting Learn more

ICER recently posted an Evidence Report assessing the comparative clinical effectiveness and value of atidarsagene autotemcel (“arsa-cel”, Orchard Therapeutics) for metachromatic leukodystrophy (MLD).

This Evidence Report will the basis for our Sept 29th virtual public meeting, where an independent appraisal committee will review the evidence, hear further testimony from stakeholders, and deliberate on the treatment’s comparative clinical effectiveness, other potential benefits, and long-term value for money. Register here.

Our Origin Story.

ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.

The ICER Impact.

New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million

Read More

Engaged with over 400 patient groups and patient reps

In a landmark international program, HTA agencies around the world can now access ICER’s customizable COVID-19 Cost-Effectiveness Model

Read More



In 2021, we celebrated our 15th anniversary! Learn more.

cheerful creative patients sitting in a circle laughing

In early 2023, ICER collaborated with NICE and CADTH on HTA methods. Learn more.

ICER podcast logo

Listen to our podcast, “A Prescription for Fair Pricing“. Subscribe now on Apple, Google, or Spotify.


Policy Papers.

Easy access to our latest policy papers

Barriers to Fair Access

Second annual scorecard of barriers to fair access criteria; during ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change

Read More

Unsupported Price Increases

Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.

Additionally, three Medicare Part B drugs with high list price increases in 2020 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $3,200 per year.

Read More

Evaluating and Advancing Health Technology Assessment Methods that Support Health Equity

ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.

Read More

Cost-Effectiveness, the evLYG,

the QALY, and Fair Drug Pricing.

Learn More.